期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他氟前列素合成纵览 被引量：1

A Survey of Synthetic Approaches to Drug Tafluprost
下载PDF
导出
摘要 目的通过对已有的他氟前列素的合成方法进行分析总结,找到价格低廉,减少污染,更适合工业化生产的合成路线。方法对他氟前列素合成方法的总结,整理,归纳。结果与结论以23为反应原料,反应成本低,绿色环保,适合工业化生产。 OBJECTIVE Through analysing the exisiting methods of synthesing of Tafliprost to find the lower price,less pollution,more suitable for industrial production of synthetic rout. METHODS The synthesing methods of Tafliprost were generalized and concluded. RESULTS and CONCLUSION Using 23 as reaction raw material has less money,less pollution,and is more suitable for industrial production.
作者 唐奇 尚广磊 张宝振 王恩思
机构地区 吉林大学药学院
出处 《海峡药学》 2016年第4期250-251,共2页 Strait Pharmaceutical Journal
关键词 青光眼 他氟前列素 合成 Glaucoma： Tafluprost Synthetic
分类号 R91 [医药卫生—药学]
  • 相关文献

参考文献9

  • 1范鸣.抗青光眼药Tafluprost[J].药学进展,2011,35(10):479-479. 被引量：2
  • 2WANG Y,BOLOS J,SERRADELL N.Tafluprost[J].Drugs Fut,2006,31(9):788-792.
  • 3MATSUMURA Y,MORI N,NAKANO T,et al.Synthesis of the highly potent prostanoid FP receptor agonist,AFP-168:anovel 15-deoxy-15,15-difluoroprostaglandin F2 alpha derivat[J].Tetrahedron Lett,2004,45(7):1527-1529.
  • 4Eiichi Shirasawa,Masaaki Kageyama,et al.Tifluoroprostaglandin derivatives and their use[P].US:5985920,1999-11-16.
  • 5Etinger Marina,Gutman Arie L,Nisnevich Gennady.Anew process for the preparation of 17-phenyl-18,19,20-trinor-PGF2 and its derivatives[P].WO:02096868,2002-12-05.
  • 6Etinger Marina,Gutman Arie L,Nisnevich Gennady.Anew process for the preparation of 17-phenyl-18,19,20-trinor-PGF2αand its derivatives[P].WO:02096868,2002-12-05.
  • 7魏士叶,叶有之,许敏冠,高立达.用于制备无异构体的前列腺素的方法和中间体[P].CN1043707862015-02-25.
  • 8杨波,彭乐.一种合成他氟前列素的新方法[P].CN103804195.2014-05-21.
  • 9陈刚,曾令国,谢建勇,李勤耕.他氟前列素的合成工艺改进[J].化学研究与应用,2014,26(5):722-727. 被引量：3

二级参考文献12

  • 1Neausu AM. Receptors involwd in the mechanism of ac- tion of topical prostaglandins [ J ]. Ofialmologia, 2009,53 (2):3-7.
  • 2Binder D, Bowler J, Brown ED, et al. 16-Aryloxypros- taglandins :a new class of potent luteolytic agent[ J]. Pros- taglandins, 1974,6( 1 ) :87-90.
  • 3Eiichi Shirasawa, Masaaki Kageyama, et al. Tifluoropros- taglandin derivatives and their use [ P ]. US: 5985920, 1999-11-16.
  • 4Yasushi Matsumura, Nobuaki Mori, et al. Synthesis of the highly potent prostanoid FP receptor agonist AFP-168:a novel 15-deoxy-15, 15-diuoroprostaglandin derivativeF2α [J]. Tetrahedron Letters,2004,45(7) :1 527-1 529.
  • 5Etinger Marina, Gutman Arie L, Nisnevich Gennady. A new process for the preparation of 17-phenyl-18,19,20- trinor-PGFα and its derivatives [ P]. WO: 02096868, 2002-12-05.
  • 6Yankee EW, Axen U, Bundy GL. Total synthesis of 15- methylprostaglandins [ J]. J Am Chern Soc, 1974,96( 18 ) : 5 865-5 876.
  • 7Corey EJ, Albonico SM, Koelliker U, Schaaf TK, VarmaRK. New reagents for stereoselective carbonyl reduction. Improved synthetic mute to the primary prostaglandins [J]. J Am Chem Soc,1971,93(6) :1 491-1 493.
  • 8Schaaf Tk, Bindra JS, Egger JF, et al. N-( Methanesulfo- nyl) -16-phenoxyprostaglandin carboxamides : tissue-selec- tive,uterine stimulants [ J ]. J Med Chem, 1981,24 ( 11 ) : 1 353-1 359.
  • 9Singh RP, Majumder U, Shreeve JM. Nucleophilic di-and tetratluorination of dicarbonyl compounds [ J ]. J Org Chem,2001,66(19) :6 263-6 267.
  • 10Robert George Syvret. Imidazolate sulfur difluorides [ P ]. EP :0933364 A1,1999-01-27.

共引文献3

同被引文献30

  • 1Neacsu A M. Receptors involved in the mechanism of action of topical prostaglandines [J]. Oftalmologia, 2009, 53(2):3-7.
  • 2Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacoiogicai characteristics of AFP- 168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug[J]. Exp Eye Res, 2004, 78(4):767-776.
  • 3Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteersfJ]. Int J Clin Pharmacol Ther, 2008,46(8):400-406.
  • 4Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males[J]. J Ocul Pharmacol Ther, 2007, 23(4):359-365.
  • 5Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension[J]. Clin Ophthalmol, 2010, 4:163-170.
  • 6Traverso C E, Ropo A, Papadia M, et al. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost[J]. J Ocul Pharmacol Ther. 2010. 26(D:97-104_.
  • 7Uusitalo H, Pillunat L E, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double- masked phase ]lI study[J]. Acta Ophthalmol, 2010, 88(1):12-19.
  • 8Kuwayama Y, Komemushi S. Intraocular pressure lowering effect of 0.001 5% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, doubie-blihd, multicenter, phase IIt study[J]. Nippon Ganka Gakkai Zasshi, 2010, 114(5):436-443.
  • 9Hamacher T, Airaksinen J, Saareia V, et al.. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis[J]. Acta Ophthalmol Suppl (Oxf) , 2008, 242:14-19.
  • 10Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers[J]. Acta Ophthalmol Suppl (Oxf), 2008, 242:7-13.

引证文献1

二级引证文献10

海峡药学
2016年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部